{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-23-065674","form_type":"8-K","ticker":"RLMD","cik":"0001553643","company_name":"RELMADA THERAPEUTICS, INC.","filed_at":"2023-08-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.279303+00:00","generated_at":"2026-06-11T17:28:05.908675+00:00","sec_items":["8.01","9.01"],"event_type":"other","sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"confidence":"low","headline":"Relmada Therapeutics updates corporate presentation; no material new information disclosed","bullets":["Company filed updated corporate presentation as Exhibit 99.1 on August 10, 2023.","Presentation titled 'Targeting Major Advances in the Treatment of CNS Disorders'.","Filing does not include specific new financial results, guidance, or milestones.","No material changes to corporate strategy or pipeline disclosed in the filing."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-23-065674","json":"https://secwatch.observer/filing/0001213900-23-065674.json","markdown":"https://secwatch.observer/filing/0001213900-23-065674.md","text":"https://secwatch.observer/filing/0001213900-23-065674.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1553643/000121390023065674/0001213900-23-065674-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1553643/000121390023065674/ea183245-8k_relmada.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T17:28:05.908675+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}